Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 3

2(33.3%)

6Total

Phase 2(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06153693Phase 3Completed

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Role: lead

NCT05968430Phase 3Active Not Recruiting

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Role: lead

NCT05769608Phase 2Completed

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

Role: lead

NCT06785454Phase 2Completed

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

Role: lead

NCT06150924Phase 2Completed

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

Role: lead

NCT05001945Phase 2Completed

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Role: lead

All 6 trials loaded